Lionsbridge Wealth Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 8,334 shares of the company’s stock after purchasing an additional 315 shares during the quarter. Johnson & Johnson comprises about 1.4% of Lionsbridge Wealth Management LLC’s holdings, making the stock its 26th biggest holding. Lionsbridge Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,472,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after acquiring an additional 2,815,655 shares in the last quarter. State Street Corp boosted its position in shares of Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after buying an additional 803,013 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Johnson & Johnson by 3.3% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after buying an additional 805,831 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after buying an additional 328,297 shares during the last quarter. Finally, California Public Employees Retirement System boosted its holdings in shares of Johnson & Johnson by 2.7% during the 3rd quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company’s stock valued at $1,919,726,000 after acquiring an additional 310,473 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors.
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. During the same period in the prior year, the company posted $2.67 EPS. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the stock. Atlantic Securities dropped their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. Guggenheim initiated coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective for the company. SVB Leerink cut their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. UBS Group began coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 5/1 – 5/5
- It’s Time To Check Into Booking.Com
- Shopify Delivers Growth And Efficiency; Shares Surge
- Advanced Micro Devices Bullish Reversal Is Still In Play
- Broadcom Shares Trade In Tight Range Ahead Of Q2 Earnings Report
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
